Dasatinib (Sprycel)
(Bristol-Myers Squibb) Oral bioavailability ranged from 14% (mouse) to 34% (dog); incomplete bioavailability because of incomplete absorption and high first-pass metabolism; not due to Pgp (195);
Vd= 2505 L Metabolized by CYP3A4; extensively metabolized with 29 metabolites resulting from oxidation; possible inhibitor of CYP3A4 and CYP2C8 140 mg orally once daily;
96% (AAG, HSA) Pleural effusions are more frequently observed in dasatinib-treated patients than imatinib-treated patients, with 10-35 % of dasatinib-treated patients developing pleural effusions (196); reversible pulmonary arterial hypertension has been observed in a small percentage of dasatinib-treated patients (197)